These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 5451983)

  • 21. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.
    Donner KM; Hiltunen TP; Suonsyrjä T; Hannila-Handelberg T; Tikkanen I; Antikainen M; Hirvonen A; Kontula K
    J Hypertens; 2009 Oct; 27(10):2001-9. PubMed ID: 19593208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The importance of plasma renin determination to the choice of therapy of renovascular hypertension (author's transl)].
    Zofková I; Hrnová Z; Dráb K; Stríbrná J; Hejnal J; Firt P; Hejhal L
    Cas Lek Cesk; 1977 Mar; 116(12):358-60. PubMed ID: 861988
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of hypertension with angiotensin converting enzyme inhibitors.
    Johnston CI; McGrath BP; Matthews PG; Jackson B
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():135-44. PubMed ID: 6183036
    [No Abstract]   [Full Text] [Related]  

  • 25. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension.
    Mayer O; Polívková H
    Cor Vasa; 1987; 29(4 Suppl 1):37-41. PubMed ID: 3315449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of long-term treatment of arterial hypertension with Ca antagonists on the renin-angiotensin-aldosterone system in diabetics. Hyporeninemic hypoaldosteronism].
    Hrnciar J; Jakubíková K; Hrnciarová M; Kreze A; Chamulová M
    Vnitr Lek; 1995 Oct; 41(10):661-6. PubMed ID: 8578695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Renin-angiotensin system in persisting orthostatic hypotension following guanacline].
    Wende W; Ochs HG
    Verh Dtsch Ges Inn Med; 1973; 79():752-4. PubMed ID: 4364050
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment and prognosis of renal hypertension].
    Oshima K; Takeda T; Fukuchi S; Abe K; Kajiwara N
    Jpn Circ J; 1974 Apr; 38():Suppl:93-7. PubMed ID: 4406378
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effects of prolonged treatment with labetalol on renal function and on water and saline metabolism in essential and reno-parenchymal hypertension].
    Valvo E; Tessitore N; Previato G; Lupo A; Lo Schiavo C; Tornieri G; Maschio G
    Minerva Nefrol; 1979; 26(1):1-3. PubMed ID: 471316
    [No Abstract]   [Full Text] [Related]  

  • 31. [Inhibition of the angiotensin I converting enzyme with SQ-14225 (captopril) in the medical treatment of severe renovascular hypertension].
    Martínez Amenós A; Caralps A; Rama H; Sarrias X; Alsina J
    Rev Clin Esp; 1981 Sep; 162(6):265-8. PubMed ID: 7036249
    [No Abstract]   [Full Text] [Related]  

  • 32. [Blood pressure and renin under treatment of hypertension with guanfacine (author's transl)].
    Rosenthal J; Jäger H
    MMW Munch Med Wochenschr; 1980 Jan; 122(4):137-40. PubMed ID: 6767938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Minimal useful dose of guanfacine in patients with essential hypertension].
    Pérez Olea J; Ortíz N; Soledad Bertoló M; Allel L; Goity C; Quevedo M
    Rev Med Chil; 1985 May; 113(5):420-4. PubMed ID: 3912882
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypertension and the renin-angiotensin system in the congenital hydronephrosis rat with non-obstructive pelviureteric junction abnormalities.
    Tauchi K; Kanehara H
    Exp Nephrol; 1996; 4(1):60-4. PubMed ID: 8788602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
    Solomon RJ; Weinberg MS
    J Clin Hypertens; 1987 Dec; 3(4):589-95. PubMed ID: 3330989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical experiences on a new derivative of aminoguanidine with hypotensive action].
    Battaglia A; Raineri A
    Clin Ter; 1966 Feb; 36(4):318-23. PubMed ID: 5941235
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical evaluation of a new antihypertensive combination (cyclazenine + presinol)].
    Ambrosioni E
    G Clin Med; 1967 Nov; 48(11):1149-62. PubMed ID: 5617984
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular complications of guanidine hydrochloride.
    Nakano KK; Tyler HR
    Ann Intern Med; 1972 Oct; 77(4):658. PubMed ID: 4642749
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of minoxidil on blood pressure and plasma renin activity in patients with essential and renal hypertension.
    Werning C
    Klin Wochenschr; 1976 Aug; 54(15):727-34. PubMed ID: 790007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [First experience in the long term treatment with the antihypertensive Guancydin including studies of the renin-angiotensin system].
    Werning C; Schweikert HU; Stiel D; Vetter W; Siegenthaler W
    Dtsch Med Wochenschr; 1970 Aug; 95(35):1756-61. PubMed ID: 5451983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.